Cortical structural differences following repeated ayahuasca use hold molecular signatures

por Mallaroni, Pablo, Mason, Natasha L., Kloft, Lilian, Reckweg, Johannes T., van Oorsouw, Kim, Ramaekers, Johannes G.
Publicado 2023

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

por Reckweg, Johannes, Mason, Natasha L., van Leeuwen, Cees, Toennes, Stefan W., Terwey, Theis H., Ramaekers, Johannes G.
Publicado 2021

The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)

por Reckweg, Johannes T., Uthaug, Malin V., Szabo, Attila, Davis, Alan K., Lancelotta, Rafael, Mason, Natasha L., Ramaekers, Johannes G.
Publicado 2022

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

por Reckweg, Johannes T., van Leeuwen, Cees J., Henquet, Cécile, van Amelsvoort, Therese, Theunissen, Eef L., Mason, Natasha L., Paci, Riccardo, Terwey, Theis H., Ramaekers, Johannes G.
Publicado 2023

Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis

por Theunissen, Eef L., Reckweg, Johannes T., Hutten, Nadia R. P. W., Kuypers, Kim P. C., Toennes, Stefan W., Neukamm, Merja A., Halter, Sebastian, Ramaekers, Johannes G.
Publicado 2021